Incyte (INCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY)

INCY 102.90

+1.3%

Nov 4 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: D.Lu	1/14/2014 6:39:56 AM
	Read Replies (1) of 3202

Incyte announces the appointment of former Novartis Oncology president Hervé Hoppenot as CEO, effective immediately. Any speculation why Friedman resigned? He did present at JP Morgan. Some interesting information about IDO1 at the JP Morgan Health Conference. From the Seeking Alpha transcript: seekingalpha.com Beyond a Phase II study of 24360, as monotherapy in ovarian cancer, we have an ongoing Phase I/II study of the compound in combination with the anti-CTLA-4 a monoclonal antibody ipilimumab in melanoma, where we are seeing early evidence for the potential clinical activity of the combination that we look forward to presenting these data at ASCO, later this year.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next